KS-TEXTRON-AVIATION
Textron Aviation today announced advanced Garmin G5000 avionics enhancements coming to the best-selling mid-size business jet, the Cessna Citation Latitude, and the flagship of the Citation family of jets, the Citation Longitude. Textron Aviation’s investments in the popular business jets, based on customer feedback, will offer greater performance and improved user experience to pilots in the new Latitude jets beginning in 2025 and the new Longitude jets in 2026.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240527032307/en/
Textron Aviation | Cessna Citation Jets (Photo: Business Wire)
The Cessna Citation Latitude and Cessna Citation Longitude are designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company.
"Citation jets offer customers performance, productivity and profitability that opens a new world of possibility in aviation and their business,” said Lannie O'Bannion, senior vice president of Global Sales & Flight Operations. "These enhancements demonstrate our commitment to continuously invest in our legendary products in order to design and deliver the best aviation experience for our customers.”
When equipped with the latest Garmin G5000 avionics suite, the Latitude and Longitude will feature an array of new advanced features and technology from Garmin, including Synthetic Vision Guidance System (SVGS) shown on the primary flight displays, that couples with Synthetic Vision Technology (SVT) to support approach minima as low as 150 ft (46 m). SVGS provides a continuous, geo-spatially correct depiction of the external scene topography, including obstacles, augmented by the display of the runway.
SVT enhancements include a 3D exocentric view of the SafeTaxi® airport environment to aid situational awareness while taxiing. SVT also displays 3D building footprints including hangars, terminals and towers, taxiways, aprons, signs and other markings to help reduce runway incursions by providing guidance while taxiing at airports contained in the SafeTaxi database. The enhancements also support pilot situational awareness by increasing topographical clarity, sharpening water and terrain boundaries, improving obstacle and powerlines display and enhancing runway and airport sign depictions. SVT introduces multiple viewpoints for the first time and integrates with the new Taxiway Routing feature that provides clarity during ground operations – particularly at large, unfamiliar and complex airports during low visibility conditions.
The Latitude and Longitude can utilize the standard ADS-B In capability for Cockpit Display of Traffic Information (CDTI) Assisted Visual Separation (CAVS). CAVS increases pilots’ traffic awareness and assists pilots in maintaining separation from preceding aircraft equipped with ADS-B out during visual approaches to landing. SURF IA also utilizes ADS-B data to provide alerts when attempting a takeoff or landing on an occupied runway.
For qualifying regions, the GDL 60 Datalink offers high-bandwidth data exchange and connectivity options, including Bluetooth, Wi-Fi and LTE networks. The GDL 60 features the ability to complete automatic wireless database downloads over network connections while the aircraft is powered off. Additionally, enhancements to the GDL 69A allow the Garmin G5000 suite to access more SiriusXM Weather products.
Cessna Citation jets are versatile and reliable business tools that enable customers to fulfil a wide range of missions. The Citation Latitude has been the world’s most-delivered midsize business jet for eight consecutive years and has proved a hit with customers due to its reliability, versatility and impressive range. The Citation Longitude is equally designed around the pilot experience, passenger comfort and overall performance, delivering an aircraft that lives up to its designation as the flagship of the Citation family of business jets.
About the Cessna Citation Latitude
The Citation Latitude midsize business jet, with a four-passenger range of 2,700 nautical miles (5,000 km) at high-speed cruise, is set apart from the competition by its combination of comfort and efficiency. The aircraft’s class-leading take-off field length of 3,580 feet provides operators with greater range out of short fields. Inside, the Citation Latitude offers an unrivaled cabin experience featuring the most open, spacious, bright and refined cabin environment in its category. With a flat floor and six feet of cabin height, innovation abounds with exceptional features designed throughout the aircraft.
About the Citation Longitude
With a range of 3,500 nautical miles (6,482 kilometers) and full fuel payload of 1,600 pounds (726 kilograms), the Citation Longitude elevates passenger experience in the super-midsize class by delivering cabin sound levels that are nearly twice as quiet as the nearest competitor, a low cabin altitude (5,950 feet/1,814 meters), more standard features and an elegant yet comfortable, bespoke interior. No other super-midsize business jet offers more range, greater payload or higher cruise speed at a lower direct operating cost.
About Textron Aviation
We inspire the journey of flight. For more than 95 years, Textron Aviation Inc., a Textron Inc. company, has empowered our collective talent across the Beechcraft, Cessna and Hawker brands to design and deliver the best aviation experience for our customers. With a range that includes everything from business jets, turboprops, and high-performance pistons, to special mission, military trainer and defense products, Textron Aviation has the most versatile and comprehensive aviation product portfolio in the world and a workforce that has produced more than half of all general aviation aircraft worldwide. Customers in more than 170 countries rely on our legendary performance, reliability and versatility, along with our trusted global customer service network, for affordable and flexible flight.
For more information, visit www.txtav.com | www.defense.txtav.com | www.scorpionjet.com.
About Textron Inc.
Textron Inc. is a multi-industry company that leverages its global network of aircraft, defense, industrial and finance businesses to provide customers with innovative solutions and services. Textron is known around the world for its powerful brands such as Bell, Cessna, Beechcraft, Pipistrel, Jacobsen, Kautex, Lycoming, E-Z-GO, Arctic Cat, Textron Systems, and TRU Simulation. For more information, visit: www.textron.com
Certain statements in this press release are forward-looking statements which may project revenues or describe strategies, goals, outlook or other non-historical matters; these statements speak only as of the date on which they are made, and we undertake no obligation to update or revise any forward-looking statements. These statements are subject to known and unknown risks, uncertainties, and other factors that may cause our actual results to differ materially from those expressed or implied by such forward-looking statements.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240527032307/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release
Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee
DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press release
Based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only medicine to significantly improve overall survival versus chemotherapy in this patient population If approved, DATROWAY could become the standard of care in this setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Produc
Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press release
SteQeyma™45mg and 90mg solution for injection via autoinjector (pre-filled pen) receives positive CHMP opinion, which will facilitate subcutaneous administration in patients with plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD)1The new autoinjector option increases convenience, enhances individual patient experience and expands administration options Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution f
Megaport Expands into India, Accelerating Global Growth with Extreme IX Acquisition18.12.2025 02:15:00 CET | Press release
Through the Extreme Exchange (IX) acquisition, Megaport gains seven Internet Exchanges and access to 40+ data centres across India’s fastest-growing digital hubs. Megaport Limited (ASX: MP1) (“Megaport”), the world’s leading Network as a Service (NaaS) provider, today announced the acquisition of Extreme IX,India’s leading Internet Exchange operator, from Extreme Labs, a Bulgaria-headquartered software and network engineering company that incubated the Extreme IX platform. The acquisition expands Megaport’s global platform into one of the world’s fastest-growing digital infrastructure markets and supports the Company’s strategy to deliver scalable, high-performance connectivity services across APAC. The acquisition establishes Megaport’s presence across seven Internet Exchanges in major Indian metros: Delhi, Kolkata, Hyderabad, Chennai, Bengaluru, Mumbai, and Pune, connecting 40+ data centres and more than 400 customers. It also accelerates Megaport’s planned market entry by nearly thr
IonQ and QuantumBasel Expand Long-Term Partnership in Next-Generation Quantum Systems17.12.2025 22:10:00 CET | Press release
Extension solidifies QuantumBasel as IonQ’s Innovation Center in Europe; adds IonQ Tempo and next-generation system to advance quantum commercialization IonQ (NYSE: IONQ), the world’s leading quantum company, today announced an expanded agreement with QuantumBasel, the quantum initiative of uptownBasel, Switzerland’s innovation campus. The extended contract grants QuantumBasel ownership of its existing IonQ Forte Enterprise system and secures ownership of a next-generation Tempo system. This new agreement brings the total deal value of the QuantumBasel and IonQ partnership to over $60 million and extends IonQ’s on-site presence in Switzerland four more years, continuing through 2029. QuantumBasel is IonQ’s official Innovation Center in Europe, serving as a hub for European industry, academia, and research institutions to explore practical quantum computing applications and access IonQ’s latest enterprise-grade systems. “Our extended partnership with QuantumBasel represents a cornerston
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom